Bryan Garnier - Oncimmune Holdings (ONC) Oncimmune: US strategic commercialisation partnership with Biodesix | BUY | 180 vs 168p (+65%)

Report

Bryan Garnier

Gary Waanders

Oncimmune: US strategic commercialisation partnership with Biodesix | BUY | 180 vs 168p (+65%)

Oncimmune - BUY | 180 vs 168p (+65%)
US strategic commercialisation partnership with Biodesix

Biodesix brings specialist focus in lung cancer diagnostics
Financial impact
Summary and outlook

01/07/2019 3 EN

Underlying

Oncimmune Holdings

Oncimmune Holdings and its subsidiaries are engaged in cancer diagnosis.

See profile

GB00BYQ94H38 London Stock Exchange United Kingdom

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Gary Waanders

Other Reports on these Companies

Hybridan

Hybridan Small Cap Feast: 24/02/2025

Our daily digest of news from UK Small Caps @HybridanLLP 24th February 2025 * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: Delistings: Argo Group (ARGO.L) left AIM today. On Friday 21st February, both Deltex Medical (DMG.L) and Tribe Technology (...

February 24, 2025 February 24, 2025 1 EN

Hardman & Co

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability. Despite this, some companies can still make extremely attractive returns for investors. ...

January 10, 2025 January 10, 2025 1 EN

Hardman & Co

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5.7%). Only 11 companies in our index saw share prices rise in 2024. Despite challenges in raising ne...

January 9, 2025 January 9, 2025 1 EN

Fielmann: margin potential unleashed

The strong improvement in aEBITDA margin in Q1 (+300bps to 24.2%) brought greater credibility to the reiterated margin target of 24% for 2025, considering that the CSSe was still well below that threshold prior to the Q1 publication (BGe: 23.1% / CSSe: 22.8%e). While remaining a bit more prudent th

May 2, 2025 May 2, 2025 1 EN

Cedric Rossi

Cedric Rossi

Fielmann: strong margin delivery in Q1 2025

Final FY24 results unveiled this morning are in line with last month's pre-release. FIE also provides an update on its Q1 performance: sales jumped by 13% (broadly in line with CSSe) whilst aEBITDA beat expectations by 11% following a 28% surge to EUR146m (CSSe: EUR131.5m). This impressive 370bp-im

April 30, 2025 April 30, 2025 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Lhyfe: EUR53m debt financing

Lhyfe yesterday announced that it has secured EUR53m debt financing for a portfolio of four green hydrogen projects. This transaction allows Lhyfe to complete the financing and refinance part of the investment already made in four units in France and Germany, with already operating and under develo

April 30, 2025 April 30, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN